Acylated aminopropanediols and analogues and therapeutic uses thereof

#This application is the US national phase of international application PCT/FR2004/000319, filed 12 Feb. 2004, which designated the U.S. and claims priority of FR 03/01688, filed 12 Feb. 2003, the entire contents of each of which are hereby incorporated by reference.

#The invention relates to novel acylated aminopropanediols and the nitrogen and sulfur analogues thereof, pharmaceutical compositions comprising same, therapeutic uses thereof, in particular for the treatment of cerebral ischemia. The invention also provides a method of preparing said derivatives.

#The inventive compounds have advantageous antioxidant and anti-inflammatory pharmacological properties. The invention also describes methods of therapeutic treatment using said compounds and pharmaceutical compositions comprising same. In particular, the inventive compounds are useful for preventing or treating stroke.

#Legends of Figures:

#FIG. 1: Structure of particular inventive compounds the preparation of which is described in examples 2, 4, 5, 6, 8, 10 to 14, 16, 18, 19, 21 and 23 and respectively noted on the figure as 1A.2, 1A.4, 1A.5, 1A.6, 1A.8, 1A.10, 1A.11, 1A.12, 1A.13, 1A.14, 1A.16, 1A.18, 1A.19, 1A.21 and 1A.23.

#FIG. 2: Evaluation of the antioxidant properties of the inventive compounds on LDL oxidation by copper (Cu).

#For easier comprehension of the text, the inventive compounds used in the examples concerning the measurement and evaluation of activity are abbreviated as follows: “Ex 2”, for instance, indicates the compound of the invention which preparation is described in example 2.

#Thin-layer chromatography (TLC) was carried out on plates coated with MERCK silica gel 60F254 0.2 mm thick. Retention factor is abbreviated Rf.

#Column chromatography was carried out on silica gel 60 with a particle size of 40-63 μm (Merck reference 9385-5000).